Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has announced that it has received market approval from the National Medical Products Administration (NMPA) for its fixed-dose combination tablets of rosuvastatin and ezetimibe. This therapy is indicated for the treatment of hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH).
This product marks the first compound preparation combining rosuvastatin and ezetimibe into a single tablet, which facilitates a reduction of over 50% in low-density lipoprotein cholesterol (LDL-C). Real-world data indicates that this combination therapy offers superior adherence compared to monotherapies with either rosuvastatin or ezetimibe alone, leading to a 42% reduction in the risk of major adverse cardiovascular events (MACE).- Flcube.com
